Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 8, 1996, Pages 1860-1865

  Kashuba, Angela D M ^a   Ballow, Charles H ^b   Forrest, Alan ^b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; PIPERACILLIN; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029795940     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.8.1860     Document Type: Article

References (35)

1. Akaike, H. 1979. Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrica 66:237-242.
2. Atwood, C. L. 1969. Optimal and efficient designs of experiments. Ann. Math. Stat. 40:1570-1602.
3. Briggs, W. L., R. W. Phelps, and G. D. Swanson. 1990. A probabilistic approach to the single-point, single-dose problem. IEEE Trans. Biomed. Eng. 37:80-84.
4. Bruno, R., M. C. IIiadis, B. Lacarelle, V. Cosson, J. W. Mandema, Y. Le Roux, G. Montay, A. Durand, M. Ballereau, M. Alasia, J. Albanese, G. Francois, A. Iliadis, and A. Frydman. 1992. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients. J. Pharmacokinet. Biopharm. 20:653-669.
5. D'Argenio, D. Z. 1981. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. Biopharm. 9:739-756.
6. D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp. Prog. Biomed. 9:115-134.
7. D'Argenio, D. Z., and A. Schumitzky. 1992. ADAPT II users guide. Biomedical simulations resource. University of Southern California, Los Angeles.
8. Debord, J., J. C. Voultoury, G. Lachatre, C. Gay, J. P. Favereau, and R. Gay. 1992. Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients. Eur. J. Clin. Pharmacol. 43: 435-136.
9. Devine, B. J. 1974. Gentamicin pharmacokinetics. Drug Intell. Clin. Pharm. 8:650-655.
10. Drusano, G. L., A. Forrest, M. J. Snyder, M. D. Reed, and J. L. Blumer. 1988. An evaluation of optimal sampling strategy and adaptive study design. Clin. Pharmacol. Ther. 44:232-238.
11. Drusano, G. L., H. C. Standiford, B. Fitzpatrick, J. Leslie, P. Tangtatsawasdi, P. Ryan, B. Tatem, M. R. Moody, and S. C. Schimpff. 1984. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob. Agents Chemother. 26: 388-393.
12. Forrest, A., C. H. Ballow, D. E. Nix, M. C. Birmingham, and J. J. Schentag. 1993. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicroh. Agents Chemother. 37:1065-1072.
13. Forrest, A., J. Hawtoff, and M. J. Egorin. 1991. Evaluation of a new program for population PK/PD analysis: applied to simulated phase 1 data. Clin. Pharmacol. Ther. 49:153.
14. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
15. Gentry, L. O. 1985. Antimicrobial activity, pharmacokinetics, therapeutic indications, and adverse reactions of ceftazidime. Pharmacotherapy 5:254-267.
16. Guay, D. R., K. Vance-Bryan, S. Gilliland, K. Rodvold, and J. Rotschafer. 1993. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J. Clin. Pharmacol. 33:918-22.
17. Honsson, M., and M. Walder. 1992. Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients. Eur. J. Clin. Microbiol. Infect. Dis. 11:15-21.
18. Jelliffe, R. W., and S. M. Jelliffe. 1972. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight. Math. Biosci. 14:17-24.
19. Jelliffe, R. W., A. Schumitzky, M. Van Guilder, M. Liu, L. Hu, P. Maire, P. Gomis, X. Barbaut, and B. Tahani. 1993. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther. Drug Monit. 15:380-393.
20. Kinowski, J. M., J. E. De La Coussaye, F. Bressolle, D. Fabre, G. Saissi, O. Bouvet, M. Galtier, and J. J. Eledjam. 1993. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob. Agents Chemother. 37:464-473.
21. Kosireg, J. L., R. M. Rospond, C. Destache, and P. Hall. 1993. Aminoglycoside forecasting in neutropenic patients with cancer. Clin. Pharmacokinet. 24:79-87.
22. Myers, C. M., and J. L. Blumer. 1983. Determination of ceftazidime in biological fluids using high-pressure liquid chromatography. Antimicrob. Agents Chemother. 24:343-346.
23. O'Callaghen, C. H., P. Acred, and P. B. Harper. 1980. GR 20263, a new broad-spectrum cephalosporin with antipseudomonal activity. Antimicrob. Agents Chemother. 17:876-883.
24. Paradis, D., F. Vallee, S. Allard, C. Bisson, N. Daviau, C. Drapeau, F. Auger, and M. LeBel. 1992. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob. Agents Chemother. 36:2085-2092.
25. Prévost, G. 1977. Estimation of a normal probability density function from samples measured with nonnegligible and nonconstant dispersion. Internal report. Adersa-Gerbias, Palaiseau, France.
26. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles. Relationships between AUC above MIC and area under the inhibitory curve (AUIC) for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann. Pharmacother. 25:1050-1057.
27. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
28. Sirgo, M. A., and S. Norris. 1991. Ceftazidime in the elderly: appropriatenes of twice-daily dosing. DICP Ann. Pharmacother. 25:284-288.
29. Stiemer, J. L., A. Mallet, J. Golmard, and J. Boisieux. 1984. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed effect model. Drug Metab. Rev. 15:265-292.
30. Thomson, A. H., and B. Whiting. 1992. Bayesian parameter estimation and population pharmacokinetics. Clin. Pharmacokinet. 22:447-467.
31. Uematsu, T. 1993. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug. Int. J. Clin. Pharmacol. Ther. Tox. 31:606-610.
32. van Dalen, R., and T. B. Vree. 1990. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med. 16(Suppl. 3):S235-S238.
33. Welage, L., R. W. Schultz, and J. J. Schentag. 1984. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob. Agent Chemother. 25:201-204.
34. Wilkinson, L. 1990. SYSTAT; the system for statistics. SYSTAT, Inc. Evanston, Ill.
35. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.